JPMorgan Chase & Co’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3,162
| Closed | -$12.4K | – | 6927 |
|
|
2023
Q3 | $12.4K | Buy |
3,162
+2,962
| +1,481% | +$11.6K | ﹤0.01% | 5266 |
|
|
2023
Q2 | $650 | Buy |
200
+4
| +2% | +$13 | ﹤0.01% | 5605 |
|
|
2023
Q1 | $1K | Buy |
196
+19
| +11% | +$97 | ﹤0.01% | 5721 |
|
|
2022
Q4 | $6K | Sell |
177
-183
| -51% | -$6.2K | ﹤0.01% | 5204 |
|
|
2022
Q3 | $15K | Buy |
360
+107
| +42% | +$4.46K | ﹤0.01% | 4997 |
|
|
2022
Q2 | $11K | Sell |
253
-772
| -75% | -$33.6K | ﹤0.01% | 5168 |
|
|
2022
Q1 | $69K | Buy |
1,025
+209
| +26% | +$14.1K | ﹤0.01% | 4894 |
|
|
2021
Q4 | $99K | Buy |
816
+234
| +40% | +$28.4K | ﹤0.01% | 4836 |
|
|
2021
Q3 | $82K | Sell |
582
-1
| -0.2% | -$141 | ﹤0.01% | 4809 |
|
|
2021
Q2 | $160K | Sell |
583
-2,813
| -83% | -$772K | ﹤0.01% | 4586 |
|
|
2021
Q1 | $726K | Buy |
3,396
+777
| +30% | +$166K | ﹤0.01% | 3838 |
|
|
2020
Q4 | $633K | Buy |
2,619
+2,246
| +602% | +$543K | ﹤0.01% | 3626 |
|
|
2020
Q3 | $36K | Buy |
373
+137
| +58% | +$13.2K | ﹤0.01% | 4374 |
|
|
2020
Q2 | $23K | Buy |
236
+16
| +7% | +$1.56K | ﹤0.01% | 4392 |
|
|
2020
Q1 | $16K | Sell |
220
-6
| -3% | -$436 | ﹤0.01% | 4398 |
|
|
2019
Q4 | $18K | Buy |
226
+1
| +0.4% | +$80 | ﹤0.01% | 4441 |
|
|
2019
Q3 | $27K | Buy |
225
+36
| +19% | +$4.32K | ﹤0.01% | 4420 |
|
|
2019
Q2 | $34K | Buy |
189
+21
| +13% | +$3.78K | ﹤0.01% | 4396 |
|
|
2019
Q1 | $27K | Sell |
168
-8
| -5% | -$1.29K | ﹤0.01% | 4430 |
|
|
2018
Q4 | $46K | Buy |
176
+114
| +184% | +$29.8K | ﹤0.01% | 4297 |
|
|
2018
Q3 | $15K | Buy |
62
+8
| +15% | +$1.94K | ﹤0.01% | 4613 |
|
|
2018
Q2 | $13K | Buy |
+54
| New | +$13K | ﹤0.01% | 4580 |
|